Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Loss

v3.22.2.2
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Condensed Consolidated Statements of Operations and Comprehensive Loss    
Revenues $ 0 $ 84
Operating expenses:    
Research and development 2,548 1,134
General and administrative (related party of $0 and $189) 5,088 4,175
Total operating expenses 7,636 5,309
Operating loss (7,636) (5,225)
Other income:    
Interest income 99 36
Consolidated net loss from continuing operations (7,537) (5,189)
Net loss attributable to noncontrolling interest 0 1
Net loss attributable to iBio, Inc. from continuing operations (7,537) (5,188)
Preferred stock dividends- iBio CDMO Tracking Stock 0 (66)
Net loss attributable to iBio, Inc. stockholders from continuing operations (7,537) (5,254)
Loss from discontinued operations (10,593) (3,751)
Net loss available to iBio, Inc. stockholders (18,130) (9,005)
Comprehensive loss:    
Consolidated net loss (18,130) (8,940)
Other comprehensive loss - unrealized loss on debt securities (10) (1)
Comprehensive loss $ (18,140) $ (8,941)
Loss per common share attributable to iBio, Inc. stockholders - basic - continuing operations $ (0.85) $ (0.60)
Loss per common share attributable to iBio, Inc. stockholders - diluted - continuing operations (0.85) (0.60)
Loss per common share attributable to iBio, Inc. stockholders - basic - discontinued operations (1.20) (0.43)
Loss per common share attributable to iBio, Inc. stockholders - diluted - discontinued operations (1.20) (0.43)
Loss per common share attributable to iBio, Inc. stockholders - basic - total (2.05) (1.03)
Loss per common share attributable to iBio, Inc. stockholders - diluted - total $ (2.05) $ (1.03)
Weighted-average common shares outstanding - basic 8,842 8,715
Weighted-average common shares outstanding - diluted 8,842 8,715